Tanya Maria Laidlaw, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Asthma, Aspirin-Induced | 56 | 2024 | 182 | 22.350 |
Why?
|
Nasal Polyps | 42 | 2023 | 360 | 12.220 |
Why?
|
Sinusitis | 45 | 2024 | 923 | 10.140 |
Why?
|
Rhinitis | 31 | 2023 | 691 | 7.670 |
Why?
|
Aspirin | 53 | 2024 | 3282 | 6.890 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 28 | 2023 | 2282 | 4.460 |
Why?
|
Desensitization, Immunologic | 18 | 2023 | 483 | 4.100 |
Why?
|
Drug Hypersensitivity | 16 | 2021 | 884 | 3.620 |
Why?
|
Respiratory Tract Diseases | 10 | 2023 | 722 | 2.790 |
Why?
|
Biological Products | 10 | 2023 | 860 | 2.610 |
Why?
|
Cyclooxygenase Inhibitors | 7 | 2021 | 371 | 1.640 |
Why?
|
Allergens | 11 | 2023 | 1320 | 1.610 |
Why?
|
Leukotrienes | 9 | 2022 | 255 | 1.600 |
Why?
|
Asthma | 17 | 2023 | 6011 | 1.590 |
Why?
|
Receptors, Leukotriene | 6 | 2019 | 123 | 1.550 |
Why?
|
Hypersensitivity | 5 | 2023 | 1102 | 1.540 |
Why?
|
Dinoprostone | 9 | 2023 | 600 | 1.510 |
Why?
|
Eosinophils | 5 | 2021 | 955 | 1.500 |
Why?
|
Mast Cells | 9 | 2021 | 1544 | 1.300 |
Why?
|
Respiration Disorders | 3 | 2023 | 371 | 1.260 |
Why?
|
Chronic Disease | 26 | 2024 | 9146 | 1.100 |
Why?
|
Eosinophilia | 5 | 2018 | 541 | 1.100 |
Why?
|
Eicosanoids | 4 | 2023 | 279 | 0.980 |
Why?
|
Leukotriene E4 | 7 | 2023 | 79 | 0.970 |
Why?
|
Immunoglobulin E | 4 | 2022 | 1463 | 0.970 |
Why?
|
Endrin | 1 | 2023 | 4 | 0.970 |
Why?
|
Interleukin-5 Receptor alpha Subunit | 2 | 2021 | 18 | 0.940 |
Why?
|
Tryptases | 3 | 2022 | 190 | 0.830 |
Why?
|
Basophils | 2 | 2021 | 389 | 0.790 |
Why?
|
Blood Platelets | 7 | 2019 | 2508 | 0.740 |
Why?
|
Receptors, Prostaglandin E, EP2 Subtype | 3 | 2016 | 40 | 0.700 |
Why?
|
Cysteine | 3 | 2015 | 874 | 0.690 |
Why?
|
Prostaglandin D2 | 3 | 2016 | 122 | 0.690 |
Why?
|
Respiratory System | 2 | 2022 | 557 | 0.670 |
Why?
|
Accidents | 1 | 2018 | 164 | 0.610 |
Why?
|
Receptors, Purinergic P2Y12 | 1 | 2018 | 132 | 0.610 |
Why?
|
Acetates | 1 | 2018 | 311 | 0.590 |
Why?
|
Cyclooxygenase 2 Inhibitors | 1 | 2019 | 320 | 0.590 |
Why?
|
Anti-Asthmatic Agents | 2 | 2018 | 536 | 0.580 |
Why?
|
Humans | 108 | 2024 | 744343 | 0.560 |
Why?
|
Diet Therapy | 1 | 2017 | 154 | 0.560 |
Why?
|
Back Pain | 1 | 2020 | 545 | 0.560 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2021 | 1213 | 0.550 |
Why?
|
Cyclooxygenase 1 | 4 | 2022 | 104 | 0.550 |
Why?
|
Coronary Vasospasm | 1 | 2016 | 88 | 0.540 |
Why?
|
Opioid-Related Disorders | 2 | 2020 | 2065 | 0.530 |
Why?
|
Exanthema | 1 | 2020 | 501 | 0.530 |
Why?
|
Otorhinolaryngologic Surgical Procedures | 1 | 2019 | 312 | 0.530 |
Why?
|
Plasma | 1 | 2018 | 575 | 0.510 |
Why?
|
Purinergic P2Y Receptor Antagonists | 1 | 2018 | 361 | 0.510 |
Why?
|
Granulocytes | 2 | 2014 | 548 | 0.500 |
Why?
|
Respiratory Hypersensitivity | 1 | 2016 | 274 | 0.490 |
Why?
|
Oxazoles | 1 | 2015 | 189 | 0.470 |
Why?
|
Quinolines | 1 | 2018 | 732 | 0.460 |
Why?
|
Airway Obstruction | 1 | 2018 | 664 | 0.450 |
Why?
|
Interleukin-5 | 4 | 2023 | 273 | 0.450 |
Why?
|
Prostaglandins | 3 | 2023 | 405 | 0.440 |
Why?
|
Analgesics, Opioid | 3 | 2023 | 3674 | 0.420 |
Why?
|
Forced Expiratory Volume | 5 | 2021 | 1743 | 0.420 |
Why?
|
Adult | 40 | 2023 | 214055 | 0.410 |
Why?
|
Respiratory Tract Infections | 1 | 2019 | 961 | 0.410 |
Why?
|
Middle Aged | 38 | 2021 | 213383 | 0.390 |
Why?
|
Platelet Activation | 5 | 2023 | 673 | 0.380 |
Why?
|
Female | 45 | 2024 | 380194 | 0.370 |
Why?
|
Thiophenes | 1 | 2015 | 588 | 0.370 |
Why?
|
Antioxidants | 1 | 2018 | 1663 | 0.370 |
Why?
|
Leukotriene C4 | 4 | 2019 | 97 | 0.370 |
Why?
|
Stem Cell Factor | 1 | 2011 | 219 | 0.370 |
Why?
|
Administration, Oral | 5 | 2023 | 3913 | 0.360 |
Why?
|
Inflammation Mediators | 3 | 2016 | 1889 | 0.360 |
Why?
|
Nasal Mucosa | 3 | 2024 | 373 | 0.350 |
Why?
|
Fatty Acids | 1 | 2017 | 1809 | 0.350 |
Why?
|
Male | 42 | 2021 | 350118 | 0.340 |
Why?
|
Receptors, IgE | 1 | 2011 | 389 | 0.340 |
Why?
|
Chest Pain | 1 | 2016 | 1114 | 0.340 |
Why?
|
Cell Adhesion Molecules | 1 | 2014 | 1602 | 0.320 |
Why?
|
Receptors, Thromboxane | 3 | 2023 | 31 | 0.320 |
Why?
|
Immunoglobulin G | 1 | 2020 | 4560 | 0.310 |
Why?
|
Thromboxane A2 | 4 | 2015 | 92 | 0.300 |
Why?
|
Ethanol | 1 | 2014 | 1342 | 0.300 |
Why?
|
Leukotriene B4 | 3 | 2017 | 294 | 0.270 |
Why?
|
Fibroblasts | 1 | 2016 | 4161 | 0.260 |
Why?
|
Drug Therapy, Combination | 1 | 2015 | 6489 | 0.260 |
Why?
|
Quality of Life | 8 | 2024 | 12804 | 0.250 |
Why?
|
Piperazines | 1 | 2015 | 2488 | 0.250 |
Why?
|
Cytokines | 2 | 2016 | 7322 | 0.240 |
Why?
|
Interleukin-4 Receptor alpha Subunit | 2 | 2021 | 45 | 0.230 |
Why?
|
Inflammation | 6 | 2023 | 10638 | 0.230 |
Why?
|
Thromboxanes | 1 | 2023 | 50 | 0.230 |
Why?
|
Leukocytes | 1 | 2012 | 2043 | 0.230 |
Why?
|
Olfactory Mucosa | 1 | 2024 | 98 | 0.230 |
Why?
|
Immunization | 2 | 2018 | 1256 | 0.220 |
Why?
|
Syndrome | 2 | 2020 | 3251 | 0.220 |
Why?
|
Interleukin-4 | 4 | 2023 | 1147 | 0.220 |
Why?
|
Homeostasis | 3 | 2023 | 3340 | 0.210 |
Why?
|
Nasal Provocation Tests | 1 | 2021 | 9 | 0.200 |
Why?
|
Receptors, Interleukin-13 | 1 | 2021 | 15 | 0.200 |
Why?
|
Aged | 19 | 2021 | 163280 | 0.200 |
Why?
|
Nasal Sprays | 1 | 2021 | 18 | 0.200 |
Why?
|
Immunotherapy | 2 | 2023 | 4445 | 0.200 |
Why?
|
Leukocyte Count | 2 | 2015 | 1588 | 0.190 |
Why?
|
Intramolecular Oxidoreductases | 4 | 2015 | 109 | 0.190 |
Why?
|
Antigens, Dermatophagoides | 2 | 2012 | 100 | 0.190 |
Why?
|
Peanut Hypersensitivity | 1 | 2023 | 163 | 0.190 |
Why?
|
Arthroplasty | 1 | 2023 | 305 | 0.180 |
Why?
|
Biological Factors | 1 | 2021 | 164 | 0.180 |
Why?
|
Carnitine | 1 | 2020 | 246 | 0.170 |
Why?
|
Placebos | 2 | 2021 | 1676 | 0.170 |
Why?
|
Bronchiectasis | 1 | 2020 | 128 | 0.170 |
Why?
|
Retrospective Studies | 10 | 2023 | 77449 | 0.170 |
Why?
|
Cyclooxygenase 2 | 2 | 2019 | 611 | 0.160 |
Why?
|
Enterocytes | 1 | 2020 | 225 | 0.160 |
Why?
|
Pulmonary Eosinophilia | 3 | 2015 | 82 | 0.160 |
Why?
|
Young Adult | 9 | 2021 | 56430 | 0.160 |
Why?
|
Peptidyl-Dipeptidase A | 1 | 2020 | 365 | 0.160 |
Why?
|
Animals | 20 | 2024 | 168757 | 0.160 |
Why?
|
Sulfides | 1 | 2018 | 165 | 0.150 |
Why?
|
France | 1 | 2019 | 517 | 0.150 |
Why?
|
HMGB1 Protein | 1 | 2019 | 133 | 0.150 |
Why?
|
Goblet Cells | 1 | 2020 | 287 | 0.150 |
Why?
|
Cross Reactions | 1 | 2019 | 841 | 0.150 |
Why?
|
Postpartum Period | 1 | 2023 | 1086 | 0.150 |
Why?
|
Cyclopropanes | 1 | 2018 | 416 | 0.150 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2021 | 10943 | 0.150 |
Why?
|
Double-Blind Method | 3 | 2021 | 12026 | 0.140 |
Why?
|
Skin Test End-Point Titration | 1 | 1996 | 1 | 0.140 |
Why?
|
Cells, Cultured | 6 | 2020 | 19229 | 0.140 |
Why?
|
Plasma Cells | 1 | 2020 | 591 | 0.140 |
Why?
|
Paranasal Sinuses | 1 | 2019 | 250 | 0.140 |
Why?
|
Group V Phospholipases A2 | 1 | 2016 | 25 | 0.140 |
Why?
|
Prostaglandins D | 1 | 2015 | 29 | 0.140 |
Why?
|
Interferon Type I | 1 | 2020 | 542 | 0.140 |
Why?
|
Virginia | 1 | 2016 | 121 | 0.140 |
Why?
|
Eosinophilic Esophagitis | 1 | 2018 | 168 | 0.140 |
Why?
|
Epitopes | 1 | 2022 | 2571 | 0.130 |
Why?
|
Hypnosis | 1 | 1996 | 82 | 0.130 |
Why?
|
Endoscopy | 3 | 2021 | 1785 | 0.130 |
Why?
|
Platelet Activating Factor | 1 | 2015 | 149 | 0.130 |
Why?
|
Chymases | 1 | 2015 | 99 | 0.130 |
Why?
|
Morbidity | 1 | 2020 | 1769 | 0.130 |
Why?
|
Respiratory Mucosa | 1 | 2018 | 427 | 0.130 |
Why?
|
Adrenal Cortex Hormones | 3 | 2022 | 1855 | 0.130 |
Why?
|
Early Diagnosis | 1 | 2020 | 1184 | 0.130 |
Why?
|
Lung | 5 | 2020 | 9856 | 0.120 |
Why?
|
Sequence Analysis, RNA | 2 | 2020 | 2012 | 0.120 |
Why?
|
Transglutaminases | 1 | 2016 | 194 | 0.120 |
Why?
|
Mice | 15 | 2024 | 81183 | 0.120 |
Why?
|
Histamine | 1 | 1996 | 507 | 0.120 |
Why?
|
Drug Utilization | 1 | 2020 | 1183 | 0.120 |
Why?
|
Immunity, Innate | 2 | 2016 | 2958 | 0.120 |
Why?
|
Serine Endopeptidases | 2 | 2020 | 1072 | 0.120 |
Why?
|
Outpatients | 1 | 2021 | 1486 | 0.120 |
Why?
|
Cerebrospinal Fluid Rhinorrhea | 1 | 2014 | 80 | 0.120 |
Why?
|
Macrophages | 2 | 2020 | 5655 | 0.120 |
Why?
|
Immune Tolerance | 1 | 2022 | 2258 | 0.110 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2022 | 2540 | 0.110 |
Why?
|
Respiratory Function Tests | 1 | 2017 | 1616 | 0.110 |
Why?
|
Medical History Taking | 1 | 2017 | 783 | 0.110 |
Why?
|
Endothelin-1 | 1 | 2015 | 314 | 0.110 |
Why?
|
Drug Tolerance | 1 | 2015 | 376 | 0.110 |
Why?
|
Patient Care | 1 | 2019 | 640 | 0.110 |
Why?
|
Acetylation | 1 | 2016 | 1085 | 0.110 |
Why?
|
Pain, Postoperative | 1 | 2023 | 1643 | 0.110 |
Why?
|
Cross-Over Studies | 1 | 2018 | 2029 | 0.110 |
Why?
|
CHO Cells | 2 | 2012 | 1406 | 0.110 |
Why?
|
Prostaglandin-Endoperoxide Synthases | 1 | 2012 | 329 | 0.100 |
Why?
|
Antibodies | 1 | 2020 | 2460 | 0.100 |
Why?
|
Cyclic AMP-Dependent Protein Kinases | 1 | 2014 | 491 | 0.100 |
Why?
|
Cricetinae | 2 | 2012 | 2472 | 0.100 |
Why?
|
Cell Proliferation | 4 | 2024 | 10481 | 0.100 |
Why?
|
Arachidonate 5-Lipoxygenase | 1 | 2012 | 144 | 0.100 |
Why?
|
Bronchoconstriction | 1 | 2012 | 143 | 0.100 |
Why?
|
Disease Management | 2 | 2019 | 2459 | 0.100 |
Why?
|
Anti-Inflammatory Agents | 1 | 2020 | 1790 | 0.100 |
Why?
|
Phenotype | 2 | 2020 | 16365 | 0.090 |
Why?
|
Health Services Needs and Demand | 1 | 2019 | 1411 | 0.090 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2016 | 789 | 0.090 |
Why?
|
Cyclic AMP | 1 | 2014 | 1472 | 0.090 |
Why?
|
Respiratory Sounds | 1 | 2014 | 696 | 0.090 |
Why?
|
Pneumonia | 2 | 2012 | 2133 | 0.080 |
Why?
|
Interleukin-13 | 2 | 2023 | 389 | 0.080 |
Why?
|
Glutathione Transferase | 1 | 2011 | 595 | 0.080 |
Why?
|
Child | 4 | 2022 | 77709 | 0.080 |
Why?
|
Prospective Studies | 4 | 2023 | 53288 | 0.080 |
Why?
|
Mental Health | 1 | 2022 | 3019 | 0.080 |
Why?
|
Massachusetts | 1 | 2020 | 8663 | 0.080 |
Why?
|
Treatment Outcome | 6 | 2021 | 63114 | 0.070 |
Why?
|
Integrins | 1 | 2012 | 846 | 0.070 |
Why?
|
Th2 Cells | 1 | 2012 | 1061 | 0.070 |
Why?
|
Mice, Knockout | 7 | 2019 | 14557 | 0.070 |
Why?
|
Adolescent | 7 | 2021 | 85781 | 0.070 |
Why?
|
Signal Transduction | 5 | 2023 | 23403 | 0.070 |
Why?
|
Severity of Illness Index | 3 | 2021 | 15540 | 0.070 |
Why?
|
Epigenesis, Genetic | 2 | 2018 | 3647 | 0.070 |
Why?
|
Communication | 1 | 2020 | 3749 | 0.070 |
Why?
|
Flow Cytometry | 2 | 2021 | 5974 | 0.070 |
Why?
|
Dyspnea | 1 | 2014 | 1303 | 0.070 |
Why?
|
Boston | 2 | 2016 | 9313 | 0.070 |
Why?
|
Epithelial Cells | 3 | 2024 | 3690 | 0.070 |
Why?
|
Reproducibility of Results | 1 | 2024 | 19905 | 0.070 |
Why?
|
Histones | 1 | 2016 | 2599 | 0.060 |
Why?
|
Single-Cell Analysis | 3 | 2021 | 2183 | 0.060 |
Why?
|
Prevalence | 1 | 2022 | 15226 | 0.060 |
Why?
|
Stem Cells | 1 | 2018 | 3567 | 0.060 |
Why?
|
Comorbidity | 1 | 2019 | 10388 | 0.060 |
Why?
|
Pilot Projects | 1 | 2017 | 8324 | 0.060 |
Why?
|
Case-Control Studies | 3 | 2018 | 21746 | 0.060 |
Why?
|
Lipid Metabolism | 1 | 2012 | 1889 | 0.060 |
Why?
|
Promoter Regions, Genetic | 1 | 2016 | 5867 | 0.060 |
Why?
|
Body Mass Index | 1 | 2022 | 12720 | 0.060 |
Why?
|
Enzyme Inhibitors | 1 | 2015 | 3798 | 0.060 |
Why?
|
Antibody-Producing Cells | 1 | 2023 | 143 | 0.060 |
Why?
|
Clinical Trials as Topic | 2 | 2020 | 7913 | 0.060 |
Why?
|
Muscle, Smooth, Vascular | 1 | 2010 | 1504 | 0.060 |
Why?
|
Cell Culture Techniques | 1 | 2011 | 1678 | 0.060 |
Why?
|
Blotting, Western | 1 | 2011 | 5179 | 0.060 |
Why?
|
Cell Movement | 1 | 2015 | 5217 | 0.050 |
Why?
|
Bone Marrow Cells | 1 | 2011 | 2513 | 0.050 |
Why?
|
Algorithms | 3 | 2020 | 13881 | 0.050 |
Why?
|
Antibodies, Monoclonal | 2 | 2019 | 9274 | 0.050 |
Why?
|
Bronchial Hyperreactivity | 2 | 2017 | 319 | 0.050 |
Why?
|
Platelet Aggregation Inhibitors | 2 | 2013 | 3068 | 0.050 |
Why?
|
Ovalbumin | 2 | 2015 | 719 | 0.050 |
Why?
|
Peptide Fragments | 1 | 2015 | 5097 | 0.050 |
Why?
|
Gene Expression | 1 | 2015 | 7799 | 0.050 |
Why?
|
Cell Line | 2 | 2020 | 15997 | 0.050 |
Why?
|
Pregnancy | 1 | 2023 | 29144 | 0.050 |
Why?
|
DNA Methylation | 1 | 2016 | 4286 | 0.050 |
Why?
|
Nasal Lavage Fluid | 1 | 2021 | 16 | 0.050 |
Why?
|
Finland | 1 | 2022 | 602 | 0.050 |
Why?
|
Protein Tyrosine Phosphatases | 1 | 2023 | 473 | 0.050 |
Why?
|
Neutrophils | 1 | 2014 | 3719 | 0.050 |
Why?
|
Protein Kinase Inhibitors | 1 | 2017 | 5535 | 0.050 |
Why?
|
Interleukin-18 | 1 | 2022 | 249 | 0.050 |
Why?
|
RNA, Messenger | 1 | 2016 | 13033 | 0.050 |
Why?
|
National Institute of Allergy and Infectious Diseases (U.S.) | 1 | 2020 | 62 | 0.050 |
Why?
|
Intercellular Adhesion Molecule-1 | 2 | 2015 | 1155 | 0.040 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2023 | 11725 | 0.040 |
Why?
|
Administration, Intranasal | 1 | 2021 | 446 | 0.040 |
Why?
|
Oxidative Stress | 1 | 2011 | 3086 | 0.040 |
Why?
|
National Health Insurance, United States | 1 | 2019 | 104 | 0.040 |
Why?
|
Antineoplastic Agents | 2 | 2016 | 13695 | 0.040 |
Why?
|
Receptor, Insulin | 1 | 2023 | 846 | 0.040 |
Why?
|
Risk Factors | 3 | 2020 | 72290 | 0.040 |
Why?
|
Injections, Subcutaneous | 1 | 2019 | 666 | 0.040 |
Why?
|
Arthralgia | 1 | 2022 | 456 | 0.040 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2021 | 841 | 0.040 |
Why?
|
Up-Regulation | 2 | 2020 | 4217 | 0.040 |
Why?
|
Gene Expression Regulation | 1 | 2016 | 12072 | 0.040 |
Why?
|
Bronchial Provocation Tests | 1 | 2017 | 227 | 0.040 |
Why?
|
Antigens | 1 | 2023 | 1466 | 0.040 |
Why?
|
Methacholine Chloride | 1 | 2017 | 233 | 0.040 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2020 | 780 | 0.040 |
Why?
|
Receptors, Virus | 1 | 2020 | 648 | 0.040 |
Why?
|
Nasal Obstruction | 1 | 2018 | 151 | 0.030 |
Why?
|
Receptors, Prostaglandin | 1 | 2015 | 57 | 0.030 |
Why?
|
Olfaction Disorders | 1 | 2018 | 222 | 0.030 |
Why?
|
Hyperplasia | 1 | 2018 | 1185 | 0.030 |
Why?
|
Irritable Mood | 1 | 1996 | 183 | 0.030 |
Why?
|
Relaxation Therapy | 1 | 1996 | 178 | 0.030 |
Why?
|
T-Lymphocyte Subsets | 1 | 2023 | 1838 | 0.030 |
Why?
|
Leukotriene Antagonists | 1 | 2015 | 127 | 0.030 |
Why?
|
Internal-External Control | 1 | 1996 | 363 | 0.030 |
Why?
|
Aged, 80 and over | 1 | 2019 | 57776 | 0.030 |
Why?
|
Receptors, Thromboxane A2, Prostaglandin H2 | 1 | 2013 | 9 | 0.030 |
Why?
|
Databases, Factual | 2 | 2019 | 7729 | 0.030 |
Why?
|
Mice, Inbred C57BL | 3 | 2019 | 21827 | 0.030 |
Why?
|
Leukotriene D4 | 1 | 2013 | 38 | 0.030 |
Why?
|
Postoperative Complications | 1 | 2016 | 15295 | 0.030 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2021 | 3870 | 0.030 |
Why?
|
Macaca mulatta | 1 | 2020 | 2375 | 0.030 |
Why?
|
Platelet Factor 4 | 1 | 2013 | 129 | 0.030 |
Why?
|
Receptors, Prostaglandin E, EP1 Subtype | 1 | 2012 | 9 | 0.030 |
Why?
|
Cell Count | 1 | 2017 | 1856 | 0.030 |
Why?
|
Bronchoalveolar Lavage Fluid | 1 | 2015 | 768 | 0.030 |
Why?
|
Autocrine Communication | 1 | 2013 | 171 | 0.030 |
Why?
|
Adenosine Diphosphate | 1 | 2013 | 425 | 0.030 |
Why?
|
Receptors, Purinergic P2 | 1 | 2013 | 153 | 0.030 |
Why?
|
Airway Resistance | 1 | 2013 | 404 | 0.030 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 1 | 2015 | 707 | 0.030 |
Why?
|
United States | 4 | 2021 | 69872 | 0.030 |
Why?
|
Consensus | 1 | 2021 | 2959 | 0.030 |
Why?
|
Platelet-Rich Plasma | 1 | 2013 | 177 | 0.020 |
Why?
|
P-Selectin | 1 | 2013 | 600 | 0.020 |
Why?
|
Chromatography, Liquid | 1 | 2015 | 976 | 0.020 |
Why?
|
Neoplasm Proteins | 1 | 2023 | 3703 | 0.020 |
Why?
|
Cost of Illness | 1 | 2020 | 1859 | 0.020 |
Why?
|
Mycobacterium tuberculosis | 1 | 2020 | 1832 | 0.020 |
Why?
|
Cricetulus | 1 | 2011 | 816 | 0.020 |
Why?
|
Influenza, Human | 1 | 2020 | 1479 | 0.020 |
Why?
|
Tandem Mass Spectrometry | 1 | 2015 | 1157 | 0.020 |
Why?
|
Tuberculosis | 1 | 2020 | 1912 | 0.020 |
Why?
|
Analysis of Variance | 1 | 1996 | 6365 | 0.020 |
Why?
|
Insurance, Health | 1 | 2019 | 2494 | 0.020 |
Why?
|
Bone Marrow Transplantation | 1 | 2015 | 2765 | 0.020 |
Why?
|
Attitude to Health | 1 | 1996 | 2052 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2015 | 4933 | 0.020 |
Why?
|
Regression Analysis | 1 | 1996 | 6459 | 0.020 |
Why?
|
Skin Tests | 1 | 2008 | 613 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2021 | 9959 | 0.020 |
Why?
|
Transcription, Genetic | 1 | 2018 | 7722 | 0.010 |
Why?
|
Computational Biology | 1 | 2016 | 3521 | 0.010 |
Why?
|
Disease Progression | 1 | 2019 | 13284 | 0.010 |
Why?
|
Health Care Costs | 1 | 2016 | 3209 | 0.010 |
Why?
|
Incidence | 1 | 2020 | 20947 | 0.010 |
Why?
|
Clinical Protocols | 1 | 2008 | 1462 | 0.010 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3133 | 0.010 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3240 | 0.010 |
Why?
|
Mice, Inbred BALB C | 1 | 2011 | 6386 | 0.010 |
Why?
|
Blood Pressure | 1 | 1996 | 8554 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 8388 | 0.010 |
Why?
|
Registries | 1 | 2015 | 8089 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2015 | 15076 | 0.010 |
Why?
|
Age Factors | 1 | 2015 | 18370 | 0.010 |
Why?
|
Membrane Proteins | 1 | 2013 | 7880 | 0.010 |
Why?
|
Prognosis | 1 | 2015 | 29063 | 0.010 |
Why?
|
HIV Infections | 1 | 2020 | 16718 | 0.010 |
Why?
|
Neoplasms | 1 | 2016 | 21683 | 0.000 |
Why?
|